Impact of Empiric Carbapenem Beta-Lactam (CBL) Versus Non-Carbapenem Beta-Lactam (N-CBL) Treatment on Mortality and Microbiological Response Rates for Third-Generation Cephalosporin-Resistant (3GCR) Enterobacteriaceae Bloodstream Infections (BSI)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.